Jazz Pharma's lung cancer drug fails late-stage trial
12/06/2026 13:04
Jazz Pharma's lung cancer drug fails late-stage trial June 12 (Reuters) - Jazz Pharmaceuticals JAZZ.O said on Friday its drug for a type of lung cancer did not meet the main goal of overall survival in a late-stage study.
(Reporting by Christy Santhosh in Bengaluru; Editing by Shilpi Majumdar)
Recent news on Jazz Pharmaceuticals
See all newsBrief: Jazz Pharmaceuticals Enters Amendment No. 4 To Credit Agreement On Sept 23, 2026
U.S. STOCKS ON THE MOVE-BWX Technologies, Synopsys,Burlington Stores
U.S. STOCKS ON THE MOVE-Jazz Pharmaceuticals, Celularity, Infleqtion
Jazz Pharma dips after upsized $1.1 bln convertible offering
Brief: Jazz Pharmaceuticals Announces Private Offering Of $1.0 Billion Of Exchangeable Senior Notes Due 2032